Share on LinkedInShare on LinkedIn

ARTICLE · 19 OCTOBER 2026

Beyond The Primary Patent: How Pharma Can Build Competitive Barriers

There is no better product, more adapted to the patent system than medicines. The cycle of development of a medicine is long—at least around 8 to 10 years—and is full of traps. At any stage of the development the medicine may fail, forcing researchers back to square one.

European UnionIntellectual Property

There is no better product, more adapted to the patent system than medicines. The cycle of development of a medicine is long—at least around 8 to 10 years—and is full of traps. At any stage of the development the medicine may fail, forcing researchers back to square one.

Therefore, pharmaceutical companies, big or small, try to increase their return on investment by exploring the market to its fullest capacity. This is where the 20 years market exclusivity provided by patents makes a huge difference. Being able to keep competitors off the market gives original developers of a medicine an advantage and enables them to recover part of the investment made during development.

Recently, it has been reported that a series of medicines will become off patent resulting in a unique opportunity for generic companies and high savings for healthcare systems.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from